News
HALO
77.81
+0.35%
0.27
Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival
Simply Wall St · 1d ago
1 Value Stock Worth Investigating and 2 Facing Headwinds
Barchart · 5d ago
Weekly Report: what happened at HALO last week (0706-0710)?
Weekly Report · 6d ago
Halozyme CEO Helen Torley disposes of 1,923 common shares worth $146,852.55
PUBT · 07/09 21:20
How Halozyme’s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story
Simply Wall St · 07/09 05:36
Weekly Report: what happened at HALO last week (0629-0703)?
Weekly Report · 07/06 09:03
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued
Simply Wall St · 07/03 20:37
Stocks to Watch: Seer, Orthofix Medical, Halozyme Therapeutics
Dow Jones · 07/02 22:57
Halozyme director Bernadette Connaughton sells 1,625 shares worth $124,370.63
PUBT · 07/02 20:43
Halozyme announces key executive leadership transition and reorganization
TipRanks · 07/02 20:31
Halozyme Therapeutics Operating Chief Caudill to Exit
Dow Jones · 07/02 20:24
Halozyme COO Cortney Caudill departs amid senior management restructure
PUBT · 07/02 20:11
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative?
Simply Wall St · 07/01 20:40
1 Surging Stock for Long-Term Investors and 2 We Brush Off
Barchart · 07/01 03:30
Halozyme director Mahesh Krishnan disposes of 7,304 shares for $547,800
PUBT · 06/30 21:26
BRIEF-Halozyme Appoints David Ramsay As President Drug Delivery
Reuters · 06/30 20:02
Halozyme names David Ramsay president of drug delivery unit
PUBT · 06/30 20:02
Press Release: Halozyme Appoints David Ramsay as President Drug Delivery
Dow Jones · 06/30 20:02
Weekly Report: what happened at HALO last week (0622-0626)?
Weekly Report · 06/29 09:03
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
NASDAQ · 06/25 10:18
More
Webull provides a variety of real-time HALO stock news. You can receive the latest news about Halozyme Thrp through multiple platforms. This information may help you make smarter investment decisions.
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.